1. Home
  2. INDP vs LAES Comparison

INDP vs LAES Comparison

Compare INDP & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • LAES
  • Stock Information
  • Founded
  • INDP 2000
  • LAES 2022
  • Country
  • INDP United States
  • LAES Switzerland
  • Employees
  • INDP N/A
  • LAES N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • LAES Semiconductors
  • Sector
  • INDP Health Care
  • LAES Technology
  • Exchange
  • INDP Nasdaq
  • LAES Nasdaq
  • Market Cap
  • INDP 15.4M
  • LAES 12.6M
  • IPO Year
  • INDP N/A
  • LAES N/A
  • Fundamental
  • Price
  • INDP $1.30
  • LAES $0.41
  • Analyst Decision
  • INDP Strong Buy
  • LAES Strong Buy
  • Analyst Count
  • INDP 1
  • LAES 1
  • Target Price
  • INDP $12.00
  • LAES $1.75
  • AVG Volume (30 Days)
  • INDP 22.7K
  • LAES 444.0K
  • Earning Date
  • INDP 11-04-2024
  • LAES 09-25-2024
  • Dividend Yield
  • INDP N/A
  • LAES N/A
  • EPS Growth
  • INDP N/A
  • LAES N/A
  • EPS
  • INDP N/A
  • LAES N/A
  • Revenue
  • INDP N/A
  • LAES $20,135,000.00
  • Revenue This Year
  • INDP N/A
  • LAES N/A
  • Revenue Next Year
  • INDP N/A
  • LAES N/A
  • P/E Ratio
  • INDP N/A
  • LAES N/A
  • Revenue Growth
  • INDP N/A
  • LAES N/A
  • 52 Week Low
  • INDP $1.03
  • LAES $0.29
  • 52 Week High
  • INDP $3.25
  • LAES $3.95
  • Technical
  • Relative Strength Index (RSI)
  • INDP 44.83
  • LAES 46.17
  • Support Level
  • INDP $1.10
  • LAES $0.37
  • Resistance Level
  • INDP $1.32
  • LAES $0.48
  • Average True Range (ATR)
  • INDP 0.11
  • LAES 0.04
  • MACD
  • INDP 0.02
  • LAES 0.00
  • Stochastic Oscillator
  • INDP 55.56
  • LAES 45.16

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. Its vaultIC range offers a complete set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

Share on Social Networks: